These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

350 related items for PubMed ID: 26710307

  • 1. AFLIBERCEPT FOR POLYPOIDAL CHOROIDAL VASCULOPATHY: As Needed Versus Fixed Interval Dosing.
    Inoue M, Yamane S, Taoka R, Arakawa A, Kadonosono K.
    Retina; 2016 Aug; 36(8):1527-34. PubMed ID: 26710307
    [Abstract] [Full Text] [Related]

  • 2. INTRAVITREAL INJECTION OF AFLIBERCEPT IN PATIENTS WITH POLYPOIDAL CHOROIDAL VASCULOPATHY: A 3-YEAR FOLLOW-UP.
    Maruyama-Inoue M, Sato S, Yamane S, Kadonosono K.
    Retina; 2018 Oct; 38(10):2001-2009. PubMed ID: 28816730
    [Abstract] [Full Text] [Related]

  • 3. Intravitreal Aflibercept and Ranibizumab Injections for Polypoidal Choroidal Vasculopathy.
    Cho HJ, Kim KM, Kim HS, Han JI, Kim CG, Lee TG, Kim JW.
    Am J Ophthalmol; 2016 May; 165():1-6. PubMed ID: 26921806
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. One-Year Results of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy.
    Yamamoto A, Okada AA, Kano M, Koizumi H, Saito M, Maruko I, Sekiryu T, Iida T.
    Ophthalmology; 2015 Sep; 122(9):1866-72. PubMed ID: 26088619
    [Abstract] [Full Text] [Related]

  • 6. Six-month results of intravitreal aflibercept injections for patients with polypoidal choroidal vasculopathy.
    Hosokawa M, Shiraga F, Yamashita A, Shiragami C, Ono A, Shirakata Y, Kimura S, Shiode Y, Kawata T, Hosogi M, Fujiwara A, Morizane Y.
    Br J Ophthalmol; 2015 Aug; 99(8):1087-91. PubMed ID: 25712826
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effectiveness of polypoidal lesion-selective photodynamic therapy with intravitreal antivascular endothelial growth factor for polypoidal choroidal vasculopathy.
    Komuku Y, Iwahashi C, Gomi F.
    Jpn J Ophthalmol; 2020 May; 64(3):265-270. PubMed ID: 32206935
    [Abstract] [Full Text] [Related]

  • 9. Prospective clinical trial of Intravitreal aflibercept treatment for PolypoIdal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month results.
    Kokame GT, Lai JC, Wee R, Yanagihara R, Shantha JG, Ayabe J, Hirai K.
    BMC Ophthalmol; 2016 Jul 27; 16():127. PubMed ID: 27465105
    [Abstract] [Full Text] [Related]

  • 10. Subfoveal choroidal thickness in polypoidal choroidal vasculopathy after switching to intravitreal aflibercept injection.
    Saito M, Kano M, Itagaki K, Ise S, Imaizumi K, Sekiryu T.
    Jpn J Ophthalmol; 2016 Jan 27; 60(1):35-41. PubMed ID: 26350229
    [Abstract] [Full Text] [Related]

  • 11. INITIAL VERSUS DELAYED PHOTODYNAMIC THERAPY IN COMBINATION WITH RANIBIZUMAB FOR TREATMENT OF POLYPOIDAL CHOROIDAL VASCULOPATHY: The Fujisan Study.
    Gomi F, Oshima Y, Mori R, Kano M, Saito M, Yamashita A, Iwata E, Maruko R, Fujisan Study Group.
    Retina; 2015 Aug 27; 35(8):1569-76. PubMed ID: 25830698
    [Abstract] [Full Text] [Related]

  • 12. ANGIOGRAPHIC FINDINGS OF RANIBIZUMAB-RESISTANT POLYPOIDAL CHOROIDAL VASCULOPATHY AFTER SWITCHING TO A TREAT-AND-EXTEND REGIMEN WITH INTRAVITREAL AFLIBERCEPT.
    Azuma K, Obata R, Nomura Y, Tan X, Takahashi H, Yanagi Y.
    Retina; 2016 Nov 27; 36(11):2158-2165. PubMed ID: 27258669
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Anti-vascular endothelial growth factor monotherapy for polypoidal choroidal vasculopathy with polyps resembling grape clusters.
    Lee JH, Lee WK.
    Graefes Arch Clin Exp Ophthalmol; 2016 Apr 27; 254(4):645-51. PubMed ID: 26138657
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Timing of Complete Polypoidal Regression after Intravitreous Aflibercept Treatments in Polypoidal Choroidal Vasculopathy.
    Chaikitmongkol V, Upaphong P, Patikulsila D, Jirarattanasopa P, Choovuthayakorn J, Watanachai N, Kunavisarut P, Ratanasukon M, Bhurayanontachai P, Ingviya T, Bressler SB, Bressler NM.
    Ophthalmol Retina; 2022 Jan 27; 6(1):21-28. PubMed ID: 33781929
    [Abstract] [Full Text] [Related]

  • 17. Three-year visual outcomes of intravitreal ranibizumab with or without photodynamic therapy for polypoidal choroidal vasculopathy.
    Sakai T, Okano K, Kohno H, Tsuneoka H.
    Acta Ophthalmol; 2016 Dec 27; 94(8):e765-e771. PubMed ID: 27237048
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of fixed-dosing aflibercept for treating polypoidal choroidal vasculopathy: 1-year results of the VAULT study.
    Lee JE, Shin JP, Kim HW, Chang W, Kim YC, Lee SJ, Chung IY, Lee JE, VAULT study group.
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar 27; 255(3):493-502. PubMed ID: 27628062
    [Abstract] [Full Text] [Related]

  • 19. Combined photodynamic therapy with intravitreal bevacizumab injections for polypoidal choroidal vasculopathy: long-term visual outcome.
    Kang HM, Koh HJ, Lee CS, Lee SC.
    Am J Ophthalmol; 2014 Mar 27; 157(3):598-606.e1. PubMed ID: 24269378
    [Abstract] [Full Text] [Related]

  • 20. Influence of submacular hemorrhage at baseline on the long-term outcomes of aflibercept treatment for typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
    Hosokawa MM, Ouchi C, Shiode Y, Kimura S, Matoba R, Morita T, Morizane Y.
    Graefes Arch Clin Exp Ophthalmol; 2024 Oct 27; 262(10):3099-3107. PubMed ID: 38625447
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.